• Leading multiple assets in malignant hematology myeloid diseases including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myelofibrosis (MF). • Program lead for the protocol development, corporate governance committees and regulatory interactions including FDA, EMA, PMDA, CDE on NDA/BLA submissions as well as IND submissions on phase 2/3 operational seamless design and phase 1/2 dose finding/dose optimization. • Standing Committee Member of BMS Hematology Protocol Review Committee (PRC) reviewing and approving all hematology studies (myeloid diseases, lymphoma, multiple myeloma as well as non-malignant hematological diseases) design, protocol amendment, statistical analysis plan, etc. • Established and co-lead of the department wide Dynamic Borrowing Working Group across all TAs as well as early phase group, medical affairs group and data sciences group.• Liaison of GBDS and Pediatric Center of Excellence (PCoE)• Conducted due diligence and business development to successfully acquiring external ADC asset.• Build and manage a group of talented statisticians.

Oncology ADC Drug Development

Oncology Studies• Phase 3 study, Keytruda (pembrolizumab) plus chemo and targeted therapy for first line cervical cancer • Phase 3 study, Keytruda in combination with Lenvima (lenvatinib) treating first line hepatocellular carcinoma (HCC). • Phase 2 and 3 studies, relapsed or refractory (R/R) classical Hodgkin’s Lymphoma (cHL) (the first hematological indication approval for Keytruda)• Phase 1b, multi-cohort, Keytruda+folfox/folfori+targeted therapy treating metastatic colorectal cancers (1L, 2L and 3L).• Integrated summary of safety (ISS) for multiple Keytruda phase 3 studies across various indications Non-oncology Studies: Infectious Disease: Phase 2 and 3 studies of Zepatier treating chronic hepatitis C. Immunology: Phase 3 study of Simponi treating non-radiographic axial spondyloarthritis (nr aSpA),Neurosciences:• Phase 3 study of verubecestat, a BACE Inhibitor, treating participants with Alzheimer’s Disease • Phase 2a/b study of double-blind, placebo-controlled study of an allosteric modulator of the M1 muscarinic receptor treating mild to moderate Alzheimer’s Disease• Phase 4 PMR study of Bridion (sugammadex) for the reversal of neuromuscular blockade induced by either rocuronium bromide or vecuronium bromide. Closely involved in designing and developing the following studies:• Phase 3 Study of randomized, open- label placebo-controlled trial of pembrolizumab (Keytruda) in combination with lag3 for 1L, 2L and 3L+ metastatic colorectal cancer• Phase 2 tissue/site agnostic study of Keytruda in subjects with advanced solid tumors containing high tumor mutation burden (hTMB). • Phase 3 study of a triplet treatment regimen (uprifosbuvir/grazoprevir/ruzasvir) in subjects with chronic HCV GT1-6 genotypesStatistical Methodology and Research: • Statistical modeling of disease-modifying treatment effect in Alzheimer's Disease • Properties of log-rank test following covariate-adaptive randomization in oncology trials

• Worked closely with biostatistics colleagues and medical officers reviewing IND and NDA submissions• Actively involved in research on statistical methods to further improve drug review and approval process including missing data and standardizations of the dataset structure